• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Saudi Journal of Gastroenterology >Sexual dysfunction in males with hepatitis C virus: Relevance to histopathologic changes and peginterferon treatment
【24h】

Sexual dysfunction in males with hepatitis C virus: Relevance to histopathologic changes and peginterferon treatment

机译：男性丙型肝炎病毒性功能障碍：与组织病理学变化和聚乙二醇干扰素治疗的相关性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aim: The frequency of sexual dysfunction (SD) is not well known in patients with chronic hepatitis C virus (HCV). In spite of the fact that histological benefits of peginterferon (Peg-IFN)/ribavirin therapy are well established, the effects on sexual health are less certain. To assess the prevalence of the SD and explore its relevance to histopathologic changes and Peg-IFN treatment. Materials and Methods: The study included 100 HCV males; all the patients completed questionnaires to assess their sexual function before and during the treatment. Results: Before treatment, SD was reported only by 12 (19.4%) and 10 (29.4%) patients of early and advanced liver fibrosis, respectively. SD during HCV treatment (with Peg-IFN and ribavirin) for liver fibrosis was significant, as 24 (70.6%) out of 34 (100%) of HCV patients had advanced fibrosis but only 20 (32.3%) out of 62 (100%) patients had early fibrosis and were sexually affected (P = 0.01). SD before treatment was found in 22 (22%) patients; 16 (16%) were >40 years old and 6 (6%) patients were ≤40 years old. SD showed highly significant (P = 0.001) difference prior to and during treatment. Pre treatment, 78 (78%) patients denied any SD and only 22 (22%) were sexually affected, while during treatment, the number of patients who were sexually affected rose to 44 (44%). The rest of the group [56 (56%)] did not report any sexual impairment. Conclusion: SD was noticed during Peg-IFN and ribavirin treatment in patients with advanced liver fibrosis. Age and advanced liver fibrosis were important factors in inducing SD. This is of key importance for clinical practice as it modifies the management of HCV patients.
机译：背景/目的：慢性丙型肝炎病毒（HCV）患者性功能障碍（SD）的发生频率尚不清楚。尽管聚乙二醇干扰素（Peg-IFN）/利巴韦林疗法的组织学益处已得到公认，但对性健康的影响尚不确定。评估SD的患病率，并探讨其与组织病理学改变和Peg-IFN治疗的相关性。资料和方法：该研究包括100名HCV男性。所有患者在治疗前和治疗过程中均完成了问卷以评估其性功能。结果：治疗前，只有12例（19.4％）和10例（29.4％）的早期和晚期肝纤维化患者报告了SD。在HCV治疗期间（含Peg-IFN和利巴韦林），SD对肝纤维化具有显着意义，因为34（100％）HCV患者中有24（70.6％）患有晚期纤维化，而62（100％）中只有20（32.3％） ）患者患有早期纤维化并受到性影响（P = 0.01）。 22例（22％）患者在治疗前发现SD; 16岁（16％）的患者年龄大于40岁，6岁（6％）的患者年龄≤40岁。 SD在治疗之前和治疗期间显示出极显着的差异（P = 0.001）。治疗前，有78名患者（78％）拒绝接受任何SD，只有22名患者（22％）受到了性影响，而在治疗过程中，受到性影响的患者人数上升到44名（44％）。该组其余[56（56％）]没有报告任何性障碍。结论：Peg-IFN和利巴韦林治疗晚期肝纤维化患者可观察到SD。年龄和晚期肝纤维化是诱发SD的重要因素。这对于临床实践至关重要，因为它改变了HCV患者的管理方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号